Eyre TA, Savage KJ, Cheah CY, El-Galaly TC, Lewis KL, McKay P, et al. CNS prophylaxis for diffuse large B-cell lymphoma. Lancet Oncol. 2022;23:e416–e426.

Article  CAS  PubMed  Google Scholar 

Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022;139:2499–511.

Article  CAS  PubMed  Google Scholar 

El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57–68.

Article  PubMed  PubMed Central  Google Scholar 

Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C. et al.Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients Groupe d’Etudes des Lymphomes de l’Adulte.Ann Oncol. 2000;11:685–90.

Article  CAS  PubMed  Google Scholar 

Bjorkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol. 2007;18:1085–9.

Article  CAS  PubMed  Google Scholar 

Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18:149–57.

Article  CAS  PubMed  Google Scholar 

Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, et al. Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas. J Clin Oncol. 2023;41:1684–94.

Article  CAS  PubMed  Google Scholar 

Foerster AK, Lauer EM, Scherer F. Clinical applications of circulating tumor DNA in central nervous system lymphoma. Semin Hematol. 2023;60:150–6.

Article  PubMed  Google Scholar 

Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A, Weller M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol. 2019;30:211–8.

Article  CAS  PubMed  Google Scholar 

Alderuccio JP, Nayak L, Cwynarski K. How I treat secondary CNS involvement by aggressive lymphomas. Blood. 2023;142:1771–83.

Wang X, Gao Y, Shan C, Lai M, He H, Bai B, et al. Association of circulating tumor DNA from the cerebrospinal fluid with high-risk CNS involvement in patients with diffuse large B-cell lymphoma. Clin Transl Med. 2021;11:e236.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551–68 e514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y, et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021;12:6770.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li N, Wang BX, Li J, Shao Y, Li MT, Li JJ, et al. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer. Cancer. 2022;128:708–18.

Article  CAS  PubMed  Google Scholar 

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481–94 e415.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150–6.

Article  CAS  PubMed  Google Scholar 

Ollila TA, Kurt H, Waroich J, Vatkevich J, Sturtevant A, Patel NR, et al. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma. Blood. 2021;137:1120–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baraniskin A, Schroers R. Liquid biopsy and other non-invasive diagnostic measures in PCNSL. Cancers. 2021;13:2665.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoon SE, Kim YJ, Shim JH, Park D, Cho J, Ko YH, et al. Plasma circulating tumor DNA in patients with primary central nervous system lymphoma. Cancer Res Treat. 2022;54:597–612.

Article  CAS  PubMed  Google Scholar 

Szadkowska P, Roura AJ, Wojtas B, Wojnicki K, Licholai S, Waller T, et al. Improvements in quality control and library preparation for targeted sequencing allowed detection of potentially pathogenic alterations in circulating cell-free DNA derived from plasma of brain tumor patients. Cancers. 2022;14:3902.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019;565:654–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng L, Duan W, Guan J, Wang K, Liu Z, Wang X, et al. Detection of glioma-related hotspot mutations through sequencing of cerebrospinal fluid (CSF)-derived circulating tumor DNA: a pilot study on CSF-based liquid biopsy for primary spinal cord astrocytoma. Neurospine. 2023;20:701–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83:235–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730–5.

Article  CAS  PubMed  Google Scholar 

Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35:2410–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh PK, Pan E. Review of rituximab in primary CNS lymphoma. J Neurol Sci. 2020;410:116649.

Article  CAS  PubMed  Google Scholar 

Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76:929–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maza S, Kiewe P, Munz DL, Korfel A, Hamm B, Jahnke K, et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol. 2009;11:423–9.

Article  PubMed  PubMed Central  Google Scholar 

Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21:1046–52. May

Article  CAS  PubMed  Google Scholar 

Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021;106:513–21.

Article  CAS  PubMed  Google Scholar 

Heger JM, Mattlener J, Schneider J, Godel P, Sieg N, Ullrich F, et al. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA. Blood. 2024;143:522–34.

Meriranta L, Alkodsi A, Pasanen A, Lepisto M, Mapar P, Blaker YN, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2022;139:1863–77.

Article  CAS  PubMed  Google Scholar 

Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8:364ra155.

Article  PubMed  PubMed Central  Google Scholar 

Rivas-Delgado A, Nadeu F, Enjuanes A, Casanueva-Eliceiry S, Mozas P, Magnano L, et al. Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study. Clin Cancer Res. 2021;27:513–21.

Article  CAS  PubMed  Google Scholar 

Alig S, Macaulay CW, Kurtz DM, Duhrsen U, Huttmann A, Schmitz C, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J Clin Oncol. 2021;39:2605–16.

Article  CAS  PubMed  PubMed Central